Recent molecular studies of fetal hemoglobin (HbF) regulation have reinvigorated the field
and shown promise for the development of clinical HbF inducers to be used in patients with …

Abstract β-Thalassemia intermedia is a clinical condition of intermediate gravity between β-
thalassemia minor, the asymptomatic carrier, and β-thalassemia major, the transfusion …

Hydroxyurea is an antimetabolite drug that induces fetal haemoglobin in sickle cell disease.
However, its clinical usefulness in β-thalassaemia is unproven. We conducted a …

Objective/background Nontransfusion-dependent β-thalassemia (NTDβT) syndromes
consist of β-thalassemia intermedia and moderate hemoglobin E/β thalassemias. They are …

Abstract β-thalassemia is caused by mutations in the β-globin locus resulting in loss of, or
reduced, hemoglobin A (adult hemoglobin, HbA, α2β2) production. Hydroxyurea treatment …

Abstract β-Thalassemia is one of the most prevalent forms of congenital blood disorders
characterized by reduced hemoglobin levels with severe complications, affecting all …

Background Hydroxyurea (hydroxycarbamide) promotes the production of foetal
haemoglobin (HbF) by reactivating gamma‐genes. Evidence has shown clinical benefits of …

Abstract Background Fetal hemoglobin (HbF) induction has shown promise for the treatment
of β-hemoglobinopathies. HbF induction in β-thalassemia could overcome ineffective …

Background Non‐transfusion dependent beta thalassaemia is a subset of inherited
haemoglobin disorders characterised by reduced production of the beta globin chain of the …

Augmentation of fetal hemoglobin (HbF) production has been an enduring therapeutic
objective in β-thalassemia patients for which hydroxyurea (HU) has largely been the drug of …